1-3 of 3
Anna Ma, MS
Close
Sort by
Journal Articles

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Daniel J. Landsburg, MD, Rod Ramchandren, MD, Yasuhiro Oki, MD, John M. Pagel, MD PhD, P.J. Lugtenburg, MD PhD, Robert Gharavi, PharmD, Anna Ma, MS, Amir Hafeez, MD, Stefan Klaus Barta, MDMRCP,MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1555.
https://doi.org/10.1182/blood.V130.Suppl_1.1555.1555
Published: 2017
Journal Articles

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Amir Hafeez, MD, Robert Gharavi, PharmD, Tania Chander, PharmD, Anna Ma, MS, Micah M. Burch, MD, Yasuhiro Oki, MD
Journal: Blood
Blood (2016) 128 (22): 5422.
https://doi.org/10.1182/blood.V128.22.5422.5422
Published: 2016
Journal Articles

Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma

Anas Younes, MD, Jesus G. Berdeja, MD, Manish R. Patel, MD, Kevin R. Kelly, MD PhD, Ian W. Flinn, MD PhD, John F Gerecitano, MD PhD, Sattva S. Neelapu, MD, Amanda R. Copeland, RN, MSN, CNS, Amy Akins, RN, BSN, CCRC, Myles Clancy, Anna Ma, MS, Kaiming Sun, PhD, Ze Tian, PhD, Jing Wang, PhD, Jaye Viner, MD MPH, Yasuhiro Oki, MD
Journal: Blood
Blood (2015) 126 (23): 257.
https://doi.org/10.1182/blood.V126.23.257.257
Published: 2015